Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Age-related Macular Degeneration
100%
Visual Acuity
100%
Myopic Choroidal Neovascularization (mCNV)
100%
Phase I Clinical Trial
100%
Ranibizumab
100%
Pro Re Nata
62%
Retinal Thickness
37%
Treatment Group
25%
Clinical Trials
12%
Adverse Events
12%
Financial Disclosure
12%
Intravitreal Injection
12%
Ocular Side Effects
12%
Systemic Side Effects
12%
Safety Profile
12%
As(III)
12%
Intravitreal Ranibizumab
12%
Ranibizumab Injection
12%
Efficacy Profile
12%
Injection Technique
12%
Angioid Streaks
12%
Ocular Histoplasmosis
12%
Pathologic Myopia
12%
Medicine and Dentistry
Clinical Trial
100%
Age Related Macular Degeneration
100%
Visual Acuity
100%
Choroidal Neovascularization
100%
Ranibizumab
100%
Adverse Event
25%
Treatment Group
25%
Arm
12%
Ocular Histoplasmosis
12%
Intravitreal Administration
12%
Angioid Streak
12%
Pathologic Myopia
12%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Age Related Macular Degeneration
100%
Subretinal Neovascularization
100%
Ranibizumab
100%
Adverse Event
33%
Treatment Group
33%
Intravitreal Administration
16%
Angioid Streak
16%
Ocular Histoplasmosis
16%
Neuroscience
Age-Related Macular Degeneration
100%
Choroidal Neovascularization
100%
Ranibizumab
100%
Visual Acuity
100%
Angioid Streak
12%
Pathologic Myopia
12%